These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 25389924)

  • 1. Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors.
    Wei IH; Harmon CM; Arcerito M; Cheng DF; Minter RM; Simeone DM
    Ann Surg; 2014 Dec; 260(6):1088-94. PubMed ID: 25389924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in 151 patients with surgically resected non-functioning pancreatic neuroendocrine tumours.
    Song KB; Kim SC; Kim JH; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
    ANZ J Surg; 2016 Jul; 86(7-8):563-7. PubMed ID: 25040037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystic pancreatic neuroendocrine tumors: outcomes of preoperative endosonography-guided fine needle aspiration, and recurrence during long-term follow-up.
    Ridtitid W; Halawi H; DeWitt JM; Sherman S; LeBlanc J; McHenry L; Coté GA; Al-Haddad MA
    Endoscopy; 2015 Jul; 47(7):617-25. PubMed ID: 25763832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal surgical management of unifocal vs. multifocal NF-PNETs: a respective cohort study.
    Kim J; Hong SS; Kim SH; Hwang HK; Kang CM
    World J Surg Oncol; 2024 Apr; 22(1):115. PubMed ID: 38671431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors.
    Genç CG; Jilesen AP; Partelli S; Falconi M; Muffatti F; van Kemenade FJ; van Eeden S; Verheij J; van Dieren S; van Eijck CHJ; Nieveen van Dijkum EJM
    Ann Surg; 2018 Jun; 267(6):1148-1154. PubMed ID: 28594340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of nonresected main-duct intraductal papillary mucinous neoplasms of the pancreas.
    Daudé M; Muscari F; Buscail C; Carrère N; Otal P; Selves J; Buscail L; Bournet B
    World J Gastroenterol; 2015 Mar; 21(9):2658-67. PubMed ID: 25759534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size.
    Kishi Y; Shimada K; Nara S; Esaki M; Hiraoka N; Kosuge T
    Ann Surg Oncol; 2014 Sep; 21(9):2882-8. PubMed ID: 24740828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-free survival after pancreatectomy for pancreatic neuroendocrine tumors: A 17-year single-center experience of 223 patients.
    Mukkala AN; Ray S; Bevacqua D; McGilvray I; Sapisochin G; Moulton CA; Gallinger S; Cleary SP; Shwaartz C; Wei AC; Reichman TW
    J Gastrointest Surg; 2024 Sep; 28(9):1485-1492. PubMed ID: 38906319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.
    Bilimoria KY; Talamonti MS; Tomlinson JS; Stewart AK; Winchester DP; Ko CY; Bentrem DJ
    Ann Surg; 2008 Mar; 247(3):490-500. PubMed ID: 18376195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of recurrence after the resection of pancreatic neuroendocrine tumors.
    Chouliaras K; Newman NA; Shukla M; Swett KR; Levine EA; Sham J; Mann GN; Shen P
    J Surg Oncol; 2018 Sep; 118(3):416-421. PubMed ID: 30259518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoregulatory Forkhead Box Protein p3-Positive Lymphocytes Are Associated with Overall Survival in Patients with Pancreatic Neuroendocrine Tumors.
    de Reuver PR; Mehta S; Gill P; Andrici J; D'Urso L; Clarkson A; Mittal A; Hugh TJ; Samra JS; Gill AJ
    J Am Coll Surg; 2016 Mar; 222(3):281-7. PubMed ID: 26809747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor.
    Yamamoto Y; Okamura Y; Uemura S; Sugiura T; Ito T; Ashida R; Kato Y; Ohgi K; Yamada M; Sasaki K; Aramaki T; Uesaka K
    Ann Surg Oncol; 2017 Aug; 24(8):2363-2370. PubMed ID: 28271173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter?
    Sallinen V; Haglund C; Seppänen H
    Surgery; 2015 Dec; 158(6):1556-63. PubMed ID: 26070847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors.
    Tan QQ; Wang X; Yang L; Chen YH; Tan CL; Zhu XM; Ke NW; Liu XB
    Medicine (Baltimore); 2020 Jun; 99(24):e20324. PubMed ID: 32541455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of neutrophil-lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophages.
    Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
    Pancreatology; 2019 Sep; 19(6):897-902. PubMed ID: 31409525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reappraisal of central pancreatectomy a 12-year single-center experience.
    Goudard Y; Gaujoux S; Dokmak S; Cros J; Couvelard A; Palazzo M; Ronot M; Vullierme MP; Ruszniewski P; Belghiti J; Sauvanet A
    JAMA Surg; 2014 Apr; 149(4):356-63. PubMed ID: 24740703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
    Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence.
    Nanno Y; Toyama H; Otani K; Asari S; Goto T; Terai S; Ajiki T; Zen Y; Fukumoto T; Ku Y
    Pancreatology; 2016; 16(5):882-7. PubMed ID: 27350059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place.
    de Mestier L; Gaujoux S; Cros J; Hentic O; Vullierme MP; Couvelard A; Cadiot G; Sauvanet A; Ruszniewski P; Richard S; Hammel P
    Ann Surg; 2015 Aug; 262(2):384-8. PubMed ID: 25185468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.